TRIUMPH-1 (NCT05929066), the Phase 3 registration trial for the obesity indication, reported topline results on May 21, 2026 : average weight loss of 28.3% at 80 weeks at the highest dose in 2,339 participants, versus 2.2% on placebo, and 30.3% at 104 weeks among participants with a BMI of 35 or above who continued in a pre-specified extension
Ther Deliv
Afhngigt af dosis taber patienterne mellem 15 % og 24 % af deres kropsvgt efter cirka 48 ugers behandling
However, reaching optimal glycemic control typically requires 12-16 weeks, particularly as the dose is gradually titrated upward according to FDA-approved protocols
So, this is really important to address
As you build your nausea-busting plan with your doctor, they might recommend meal plans and certain foods to avoid